Compare DSP & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | CCCC |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 185.1M |
| IPO Year | 2021 | 2020 |
| Metric | DSP | CCCC |
|---|---|---|
| Price | $8.79 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $18.50 | $7.25 |
| AVG Volume (30 Days) | 177.5K | ★ 891.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | 43.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $289,235,000.00 | $35,584,000.00 |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $17.72 | N/A |
| P/E Ratio | $93.83 | ★ N/A |
| Revenue Growth | 29.74 | ★ 71.44 |
| 52 Week Low | $8.11 | $1.09 |
| 52 Week High | $21.83 | $3.64 |
| Indicator | DSP | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 27.78 | 63.45 |
| Support Level | $8.22 | $2.13 |
| Resistance Level | $9.20 | $2.52 |
| Average True Range (ATR) | 0.66 | 0.15 |
| MACD | -0.18 | 0.06 |
| Stochastic Oscillator | 1.14 | 95.33 |
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.